Abstracts - faqs.org

Abstracts

Business, regional

Search abstracts:
Abstracts » Business, regional

AstraZeneca counts on robots to speed search

Article Abstract:

The London-based drugmaker AstraZeneca P.L.C. has opened a fifth new building in Delaware that is robotic, fully automated chemical compound management and storage facility, which helps in speeding discovery of innovative medicines. It has invested $500 million on 170 acres and developed two million square feet of office and laboratory space at Concord Pike and Route 141 in Fairfax outside Wilmington.

Author: Loyd, Linda
Publisher: Philadelphia Newspapers, Inc.
Publication Name: Philadelphia Inquirer (PA)
Subject: Business, regional
ISSN: 0885-6613
Year: 2004
Facilities & equipment, Buildings and facilities

User Contributions:

Comment about this article or add new information about this topic:

CAPTCHA


Glaxo flu vaccine is offered to FDA: The drug maker is seeking speedy approval for selling its Fluarix in the U.S. to help with the expected shortage

Article Abstract:

GlaxoSmithKline P.L.C. is in talks with the U.S. Food and Drug Administration about selling its Fluarix influenza vaccine in the US in 2004, as there is an expected flu-vaccine shortage. Glaxo is exploring ways to supply doses and is working on a long-term plan to increase production as its main flu-vaccine-manufacturing plant in Dresden.

Author: Loyd, Linda
Publisher: Philadelphia Newspapers, Inc.
Publication Name: Philadelphia Inquirer (PA)
Subject: Business, regional
ISSN: 0885-6613
Year: 2004
United States, Market information - general, Contracts & orders received, Contracts & orders let, Supply and demand, Contracts, Influenza vaccines, Contract agreement, United States. Food and Drug Administration, GlaxoSmithKline PLC, Fluarix (Vaccine)

User Contributions:

Comment about this article or add new information about this topic:

CAPTCHA


AstraZeneca will delay drug: It said more testing was needed for Galida, a diabetes medication. The news disappointed investors

Article Abstract:

AstraZeneca P.L.C., Almond based drug company announced that the regulatory filing of Galida, which is a late-stage diabetes medicine will be delayed till 2007 for further test. The delay resulted as the United States regulators called for a worldwide regulatory-authority review of the safety and toxicology of Galida.

Author: Loyd, Linda
Publisher: Philadelphia Newspapers, Inc.
Publication Name: Philadelphia Inquirer (PA)
Subject: Business, regional
ISSN: 0885-6613
Year: 2004
Product information, Management dynamics, Surgical and Medical Instrument Manufacturing, Surgical and medical instruments, Diabetes Tests & Equip, Management, Testing, Company business management, Diabetes therapy equipment

User Contributions:

Comment about this article or add new information about this topic:

CAPTCHA


Subjects list: United Kingdom, Pharmaceutical industry, AstraZeneca PLC, AZN
Similar abstracts:
  • Abstracts: Auto rates to drop, not plunge. Big grant to oil firm shrouded in secrecy: Citgo will not discuss the $15.7 million it got in federal port security aid
  • Abstracts: Penn adds 5 hospitals to health-care network. Aetna-Jefferson dispute leaves employers wary. (Workers at Jefferson Health Systems hospital contest Aetna U.S. Healthcare benefit contract)
  • Abstracts: Microsoft sets sights on small businesses: The software-maker sees that sector as the next cash cow. profit regained - but paradise lost at Rodale
  • Abstracts: Delta cuts fares for travel in US. Oil prices rise despite OPEC plan. Economic stiletto fells Dan's
  • Abstracts: Cisco shares fall 11% after its optimism on sales fades. Long search is over for Google. Disney rollercoaster in ledgers, not parks
This website is not affiliated with document authors or copyright owners. This page is provided for informational purposes only. Unintentional errors are possible.
Some parts © 2025 Advameg, Inc.